Company intelligence / Profile preview

Corteria Pharmaceuticals

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Corteria has initiated a Phase 1 study for its lead candidate COR-1167, a once-daily subcutaneous CRF2 agonist for worsening heart failure. The randomized placebo-controlled study is assessing safety and tolerability in both healthy volunteers and patients with chronic heart failure.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: CRF2 agonistsMonoclonal antibodies
Industry: Biotech

Drug pipeline

3 assets

COR-1167

2 more assets in the full pipeline.

Request access →

Partnerships

Sanofi (in-licensed programs)

Beyond the preview

Go deeper on Corteria Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corteria Pharmaceuticals.

Explore the full profile